Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
[google_news title=”” keyword=”Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene Therapy
- Retrovirus-Based Gene Therapy Drugs Market to Reach USD 14.2 Billion by 2033, Growing at 21.1% CAGR | Marketresearch.biz Studyon May 17, 2024 at 6:00 am
Marketresearch.biz reports that the The Global Retrovirus-Based Gene Therapy Drugs Market size is expected to be worth around USD 14.2 Billion by 2033, from USD 2.2 Billion in 2023, growing at a CAGR of 21.
- New gene delivery vehicle shows promise for human brain gene therapyon May 16, 2024 at 11:00 am
In an important step toward more effective gene therapies for brain diseases, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that uses a human protein to efficiently cross the blood-brain barrier and deliver a disease-relevant gene to the brain in mice expressing the human protein.
- Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Supporton May 15, 2024 at 7:18 pm
The company’s clinical-stage gene therapy pipeline, particularly TSHA-102, is approaching significant milestones with the upcoming release of pediatric data at the IRSF meeting. This event is anticipated to be a crucial catalyst, as it will be the first ...
- Early Hints at a Gene Therapy Cure for Herpeson May 15, 2024 at 3:33 am
Key Takeaways Gene therapy could provide a first-ever cure for herpes Lab mice given the therapy had a 90% or more reduction in the oral herpes virus Researchers are working on a similar therapy for genital herpes WEDNESDAY,
- Great Ormond Street hoping to license gene therapy for ‘bubble baby’ syndromeon May 13, 2024 at 10:03 pm
Hospital to take unprecedented step after drug firm pulled out despite successful trial of treatment
via Bing News